BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 16842254)

  • 1. Expression of c-erbB-4 in medulloblastoma and its correlation with prognosis.
    Bal MM; Das Radotra B; Srinivasan R; Sharma SC
    Histopathology; 2006 Jul; 49(1):92-3. PubMed ID: 16842254
    [No Abstract]   [Full Text] [Related]  

  • 2. Does c-erbB-2 expression have a role in medulloblastoma prognosis?
    Bal MM; Das Radotra B; Srinivasan R; Sharma SC
    Indian J Pathol Microbiol; 2006 Oct; 49(4):535-9. PubMed ID: 17183845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) expression in childhood brain tumors.
    Bodey B; Kaiser HE; Siegel SE
    In Vivo; 2005; 19(5):931-41. PubMed ID: 16097449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence in medulloblastoma - influence of clinical, histological and immunohistochemical factors.
    Srikantha U; Balasubramaniam A; Santosh V; Somanna S; Bhagavatula ID; Ashwathnarayana CB
    Br J Neurosurg; 2010 Jun; 24(3):280-8. PubMed ID: 20465457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.
    Milde T; Oehme I; Korshunov A; Kopp-Schneider A; Remke M; Northcott P; Deubzer HE; Lodrini M; Taylor MD; von Deimling A; Pfister S; Witt O
    Clin Cancer Res; 2010 Jun; 16(12):3240-52. PubMed ID: 20413433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines.
    Caracciolo V; D'Agostino L; Dráberová E; Sládková V; Crozier-Fitzgerald C; Agamanolis DP; de Chadarévian JP; Legido A; Giordano A; Dráber P; Katsetos CD
    J Cell Physiol; 2010 May; 223(2):519-29. PubMed ID: 20162618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival.
    Zitterbart K; Zavrelova I; Kadlecova J; Spesna R; Kratochvilova A; Pavelka Z; Sterba J
    Acta Neuropathol; 2007 Dec; 114(6):641-50. PubMed ID: 17912537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma.
    Gilbertson RJ; Perry RH; Kelly PJ; Pearson AD; Lunec J
    Cancer Res; 1997 Aug; 57(15):3272-80. PubMed ID: 9242460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of prognosis in children with medulloblastoma by using immunohistochemical analysis and tissue microarray.
    Shim KW; Joo SY; Kim SH; Choi JU; Kim DS
    J Neurosurg Pediatr; 2008 Mar; 1(3):196-205. PubMed ID: 18352763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative analysis of proliferating cell nuclear antigen and epidermal growth factor receptor expression in glial tumours: correlation with histological grading.
    Mottolese M; Natali PG; Coli A; Bigotti G; Benevolo M; Cione A; Raus L; Carapella CM
    Anticancer Res; 1998; 18(3B):1951-6. PubMed ID: 9677449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior.
    Min HS; Lee YJ; Park K; Cho BK; Park SH
    Acta Neuropathol; 2006 Jul; 112(1):13-20. PubMed ID: 16691420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion.
    Marchetti D; Mrak RE; Paulsen DD; Sinnappah-Kang ND
    J Exp Clin Cancer Res; 2007 Mar; 26(1):5-23. PubMed ID: 17550129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
    Haberler C; Slavc I; Czech T; Gelpi E; Heinzl H; Budka H; Urban C; Scarpatetti M; Ebetsberger-Dachs G; Schindler C; Jones N; Klein-Franke A; Maier H; Jauk B; Kiefer A; Hainfellner JA
    Eur J Cancer; 2006 Nov; 42(17):2996-3003. PubMed ID: 16996732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin.
    Lyons SA; O'Neal J; Sontheimer H
    Glia; 2002 Aug; 39(2):162-73. PubMed ID: 12112367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Medulloblastoma and pituicytoma].
    Sano K
    No To Shinkei; 1969 Aug; 21(8):850-1. PubMed ID: 4309370
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression.
    de Haas T; Hasselt N; Troost D; Caron H; Popovic M; Zadravec-Zaletel L; Grajkowska W; Perek M; Osterheld MC; Ellison D; Baas F; Versteeg R; Kool M
    Clin Cancer Res; 2008 Jul; 14(13):4154-60. PubMed ID: 18593994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of c-jun and c-fos oncogene in medulloblastoma and its clinical significance].
    Li YY; Mao BY; Dong XH
    Zhonghua Wai Ke Za Zhi; 2004 Feb; 42(4):213-5. PubMed ID: 15062038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 expression inversely correlates with tumour cell differentiation in medulloblastoma.
    Schüller U; Schober F; Kretzschmar HA; Herms J
    Neuropathol Appl Neurobiol; 2004 Oct; 30(5):513-21. PubMed ID: 15488027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinicobiological model predicting survival in medulloblastoma.
    Ray A; Ho M; Ma J; Parkes RK; Mainprize TG; Ueda S; McLaughlin J; Bouffet E; Rutka JT; Hawkins CE
    Clin Cancer Res; 2004 Nov; 10(22):7613-20. PubMed ID: 15569993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.